首页> 美国卫生研究院文献>The Journal of Molecular Diagnostics : JMD >Rational Error Elimination Approach to Evaluating Molecular Barcoded Next-Generation Sequencing Data Identifies Low-Frequency Mutations in Hematologic Malignancies
【2h】

Rational Error Elimination Approach to Evaluating Molecular Barcoded Next-Generation Sequencing Data Identifies Low-Frequency Mutations in Hematologic Malignancies

机译:评估分子条形码下一代测序数据的理性消除错误方法可确定血液系统恶性肿瘤的低频突变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The emergence of highly sensitive molecular diagnostic approaches, such as droplet digital PCR, has allowed the accurate identification of low-frequency variant alleles in clinical specimens; however, the multiplex capabilities of droplet digital PCR for variant detection are inadequate. The incorporation of molecular barcodes or unique IDs into next-generation sequencing libraries through PCR has enabled the detection of low-frequency variant alleles across multiple genomic regions. However, rational library preparation and sequencing data analytic strategies that integrate molecular barcodes have rarely been applied to clinical settings. In this study, we evaluated the parameters that are crucial in the use of molecular barcodes in next-generation sequencing for genotyping clinical specimens from patients with hematologic malignancies. The uniform incorporation of molecular barcodes into DNA templates through PCR was found to be crucial, and the extent of uniformity was governed by multiple interdependent variables. An error elimination strategy was developed for removing sequencing background errors by using molecular barcode sequence information as an alternative to the conventional error correction approach. This approach was successfully used to identify mutations with frequencies as low as 0.15%, and the clonal heterogeneity of hematologic malignancies was revealed. These findings have implications for elucidating heterogeneity and temporal and spatial clonal evolution, evaluating response to therapy, and monitoring relapse in patients with hematologic malignancies.
机译:高度敏感的分子诊断方法的出现,例如液滴数字PCR,已经可以准确鉴定临床标本中的低频变异等位基因。但是,液滴数字PCR用于变异检测的多重能力不足。通过PCR将分子条形码或唯一ID整合到下一代测序文库中,可以检测跨多个基因组区域的低频变异等位基因。但是,整合分子条形码的合理的文库制备和测序数据分析策略很少应用于临床。在这项研究中,我们评估了在下一代测序中使用分子条形码对血液学恶性肿瘤患者的临床标本进行基因分型至关重要的参数。发现通过PCR将分子条形码均匀地掺入DNA模板是至关重要的,并且均匀程度受多个相互依赖的变量控制。开发了一种错误消除策略,通过使用分子条形码序列信息作为常规错误纠正方法的替代方法来消除测序背景错误。该方法已成功用于鉴定频率低至0.15%的突变,并揭示了血液系统恶性肿瘤的克隆异质性。这些发现对于阐明异质性和时空克隆演变,评估对治疗的反应以及监测血液系统恶性肿瘤患者的复发具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号